5 unchanged sentences
officer, as appropriate, to allow timely decisions regarding required disclosure.
+Added: NeuroOne Medical Technologies Corporation
designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed
8 unchanged sentences
future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
−Removed: Under the supervision of and with the participation
−Removed: of our management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure
−Removed: controls and procedures, as such term is defined in Rules 13a-15(e) and 15(d- 15(e) promulgated under the Exchange Act as of March 31,
−Removed: Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
−Removed: and procedures were effective as of March 31, 2022.
+Added: the supervision of and with the participation of our management, including our principal executive officer and principal financial officer,
+Added: we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15(d- 15(e)
+Added: promulgated under the Exchange Act as of June 30, 2022.
+Added: Based on this evaluation, our principal executive officer and principal financial
+Added: officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.
in Internal Control Over Financial Reporting
were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter
−Removed: ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal
+Added: ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
+Added: NeuroOne Medical Technologies Corporation
II – OTHER INFORMATION
Legal Proceedings
−Removed: The material legal
−Removed: proceedings in which we are involved are discussed in Note 4, “Commitments and Contingencies – Legal” of the Notes
−Removed: to the Condensed Financial Statements in this Quarterly Report on Form 10-Q, and are hereby incorporated by reference.
+Added: The material legal proceedings in which we are
+Added: involved are discussed in Note 4, “Commitments and Contingencies – Legal” of the Notes to the Condensed Financial Statements
+Added: in this Quarterly Report on Form 10-Q, and are hereby incorporated by reference.
+Added: addition to the other information set forth elsewhere in this Report, you should carefully consider the factors discussed in Part I,
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.